Selecta Biosciences will successfully move on to a phase 3 clinical program before the end of the year since they presented more positive data from an ongoing phase 2 trial of gout treatment. SEL-212, a monthly regimen combined the formulations of rapamycin and pegylated uricase (pegsiticase), which helped the patients in gaining more control on over-secretion of serum uric acid. Nearly 81% of patients showed positive results within 12 weeks when compared with the uricase therapy of Horizon Pharma.

Previous interim data reported negative results due to which the stock value of Selecta Biosciences dropped down at once by 20% in premarket trading. It was then recovered in a remarkable manner by touching the never seen before peak level.

Werner Cautreels, the president and CEO of Selecta said, “We are very pleased with this continued improvement in clinical activity observed in this expanded patient data set presented today at EULAR, and believe it further demonstrates SEL-212’s potential ability to change the chronic severe gout treatment paradigm by providing better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared retrospectively to Krystexxa.”

Werner Cautreels further added, “We are now in the fourth treatment cycle of patients receiving five monthly doses of the combination treatment of SEL-212 and plan to report data from those patients at an upcoming medical meeting in the third quarter of this year.”